CFRX - ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

• Shares of micro-cap biotech ContraFect ( NASDAQ: CFRX ) plunged ~76% after hours as a data safety board recommended that the company's DISRUPT trial be stopped.
• The Data Safety and Monitoring Board (DSMB) recommended such an action "because the conditional power of the study was below the pre-specified threshold for futility," CFRX said in a statement on Wednesday.
• ContraFect's ( CFRX ) phase 3 DISRUPT trial was investigating the company's lysin exebacase in about 350 patients with complicated S. aureus bacteremia, which is the presence of the bacteria Staphylococcus aureus in the bloodstream.
• The DSMB's recommendation was based on an interim analysis of the clinical response rate of 84 patients in the trial at day 14, which was also the main goal of the study.
• "While further review of the data is ongoing, the company is initiating steps to notify investigators that patient enrollment in the trial is being stopped based on the DSMB recommendation," CFRX added.

For further details see: